Executive interview – Silence Therapeutics

Published on 18 July 2019
 

In this interview with David Horn Solomon, CEO of Silence Therapeutics, he discusses today’s announcement of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals to develop and commercialise RNAi drugs.

Share this with friends and colleagues

You may also be interested in these

Executive interview – VolitionRX

Healthcare
13 August 2019

Bitesize briefing: Changes to the Australian spodumene concentrate production landscape

Metals & mining Insight
12 August 2019

Executive interview – Snow Lake Resources

Metals & mining Insight
12 August 2019

Bitesize briefing – Do projects with lower capex and opex intensity have higher market valuations?

Metals & mining Insight
5 August 2019

Cookies

This site uses cookies: Find out more.